Source: Annual Congress 2006 - Airway cell biology I
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
M. A. Dentener, E. C. Creutzberg, E. M. Mercken, G. T. Rijkers, E. F. Wouters (Maastricht, Horn, Utrecht, Netherlands). Better characterization of local inflammation in COPD: detection of new biomarkers in exhaled breath condensate. Eur Respir J 2006; 28: Suppl. 50, 4286

Member's Comments

No comment yet.

Related content which might interest you: Prediction of CF exacerbations by FeNO and non-invasive inflammatory markers in exhaled breath condensate Source: Annual Congress 2008 - Cystic fibrosis: novel aspects of airway function and inflammation Year: 2008 Exhaled breath condensate biomarkers in COPD Source: Eur Respir J 2008; 32: 472-486 Year: 2008 Exhaled breath condensate sample collection: standards and open issues Source: Eur Respir Monogr 2010; 49: 152-161 Year: 2010 Prediction of asthma exacerbations in children by FeNO and non-invasive inflammatory markers in exhaled breath condensate Source: Annual Congress 2008 - Assessment of inflammation, hyperresponsiveness and response to exercise in asthmatic children Year: 2008 Correlation between lung function and exhaled breath condensate biomarkers of inflammation in pulmonary diseases Source: Annual Congress 2009 - Lung function in adults and children Year: 2009 Identifying biomarkers of loss of control/exacerbations in asthma from exhaled breath Source: ERS Lung Science Conference 2016 Year: 2016 Markers of airway diseases in exhaled breath condensate and their clinical value Source: School Course 2013 - Monitoring of asthma, COPD and other airway diseases Year: 2013 Is the analysis of torbamycin in exhaled breath condensate a diagnostic tool to monitor pulmonary drug deposition? Source: Eur Respir J 2004; 24: Suppl. 48, 386s Year: 2004 Inflammatory markers in exhaled breath condensate of two COPD phenotypes Source: Eur Respir J 2005; 26: Suppl. 49, 260s Year: 2005 Periostin in exhaled breath condensate as a biomarker of different severe asthma phenotypes. Source: International Congress 2017 – Systemic and airway biomarkers Year: 2017 Exhaled breath condensate for evaluation of inflammation in COPD patients Source: Eur Respir J 2006; 28: Suppl. 50, 35s Year: 2006 Changes in exhaled breath condensate in asthma and COPD: A full analysis of mass-spectra Source: Annual Congress 2010 - Exhaled biomarkers: smells like disease Year: 2010 Detection of pepsin in sputum and exhaled breath condensate: could it be a useful marker for reflux-related respiratory disease? Source: Annual Congress 2009 - What is new in the regulation and monitoring of airway function? Year: 2009 Semi-volatile organic compounds in exhaled breath condensate: a new approach in the differential diagnosis of asthma and COPD Source: Annual Congress 2009 - Asthma assessment and original therapeutic approaches Year: 2009 Technical problems with measurements of biomarkers - exhaled breath condensate Source: ERS Skills course - Biomarkers and functional assessment of obstructive lung diseases Year: 2017 Metabolomic analysis of exhaled breath condensate in diagnostics of obstructive airway diseases Source: Annual Congress 2011 - Role of the biomarkers in airway diseases Year: 2011 Increased nitrosative stress in COPD airways: validation and measurement in exhaled breath condensate Source: Annual Congress 2009 - COPD: from biomarker profiling to clinical assessment Year: 2009 Detection and characterisation of extracellular vesicles in exhaled breath condensate and sputum of COPD and severe asthma patients Source: Eur Respir J, 58 (2) 2003024; 10.1183/13993003.03024-2020 Year: 2021 The validation of assays used to measure biomarkers in exhaled breath condensate Source: Eur Respir J 2008; 32: 1408-1409 Year: 2008 Exhaled breath condensate - a new tool for assessment of idiopathic pulmonary fibrosis? Source: International Congress 2018 – News on the diagnosis of idiopathic interstitial pneumonia Year: 2018